Founder/CEO/Chairman
Eric L Keller, J.D.
Eric is a proven business and legal executive with nearly 30 years of experience in life sciences-based companies. In addition to his role as Founder and CEO of Response Pharmaceutical, he is the Founder and CEO of Redux Therapeutics, a therapeutic asset acquisition and development company.
Co-Founder/CSO
Paul Sweetnam, Ph.D.
Paul has over 25 years of experience in senior scientific and management roles in pharmaceuticals and biotechnology. Notably, he led the discovery of RDX-002 at Surface Logix, Inc. and contributed to transitioning eight candidate molecules into clinical development at Bayer Healthcare, including Nexavar.
Chief Medical Officer
William Sasiela, Ph.D.
Bill has focused his career on developing therapeutics combating cardiometabolic diseases. During his 25 year tenure in the biopharmaceutical and biotech industry, Bill has played crucial roles in developing groundbreaking cardiovascular and metabolic drugs, including Lipitor, Juxtapid, Praluent, Evkeeza, and Nexletol. His expertise in clinical development of cardiometabolic therapies is widely recognized in the industry.
Chief Regulatory Officer
Craig M. Audet, Ph.D.
Craig held leadership roles at Pfizer, Sanofi, Arena Pharmaceuticals, and Evofem Biosciences, and has 36+ years experience in pharmaceuticals and medical devices. Craig started with combination products has extensive expertise in regulatory strategy across all stages of development and has been involved in development and commercialization of numerous therapeutics. He and holds degrees from Boston College and Walden University.
Management
SVP Development
John W. Ferkany, Ph.D.
John has been instrumental at Response since its beginning. He significantly aided the development and trials of RDX-002, drawing on extensive scientific and drug development expertise . He holds degrees from the University of Michigan, University of Texas, and Johns Hopkins.
Senior Vice President, Operations
Sabine Bisson. Ph.D.
Sabine is an accomplished leader in the biotech industry with nearly 20 years of experience. Spearheading drug development efforts across the R&D lifecycle and played a key role in the development of many lifesaving therapeutics, including the CV metabolism drug PRALUENT®, and the Immuno-Oncology agent LIBTAYO® . Trained in Germany, Canada, and the US, Sabine has focused her career on creating innovative therapies for patients with high unmet medical needs.
Head, Clinical Operations
Linda Zamarka M.S.
Linda is a Drug Development Executive with over 30 years of experience, primarily at Pfizer, specializing in clinical operations and trials across multiple therapeutic areas. She has led global programs and managed regulatory submissions and vendor relationships. Linda holds a B.S. in Biology and an M.S. in Clinical Research and Biostatistics.